Pulse Biosciences (PLSE) Liabilities and Shareholders Equity (2015 - 2025)

Pulse Biosciences has reported Liabilities and Shareholders Equity for 11 years, with the latest figure at $94.5 million in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 28.63% year-over-year to $94.5 million; the trailing twelve-month figure through Dec 2025 stood at $456.9 million (up 45.01% YoY), and the FY2025 full-year result was $94.5 million, down 28.63% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $94.5 million, down from $108.8 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $133.4 million in Q1 2025, with the low at $39.5 million in Q1 2022.
• Average Liabilities and Shareholders Equity over 5 years is $78.7 million, with a median of $76.3 million recorded in 2022.
• Year-over-year, Liabilities and Shareholders Equity sank 50.92% in 2022 and surged 197.44% in 2025.
• Tracing PLSE's Liabilities and Shareholders Equity over 5 years: stood at $59.2 million in 2021, then soared by 31.65% to $77.9 million in 2022, then declined by 24.04% to $59.2 million in 2023, then jumped by 123.92% to $132.5 million in 2024, then decreased by 28.63% to $94.5 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $94.5 million (Q4 2025), $108.8 million (Q3 2025), and $120.3 million (Q2 2025), per Business Quant data.

Peer Comparison